Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
5(62.5%)
Phase 2
3(37.5%)
8Total
Phase 1(5)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05873062Phase 1Completed

Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK

Role: lead

NCT04158453Phase 1Completed

Safety, Blood Levels and Effects of AUT00201

Role: lead

NCT03164876Phase 1Completed

Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.

Role: lead

NCT02345031Phase 2Completed

Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss

Role: lead

NCT02935725Phase 1Completed

A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males

Role: lead

NCT02832128Phase 2Completed

Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)

Role: lead

NCT02589262Phase 1Completed

Safety, Blood Levels and Effects of AUT00206

Role: lead

NCT02315508Phase 2Completed

Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo

Role: lead

All 8 trials loaded